mercaptopurine 2care4 50 mg tablett
2care4 generics aps - merkaptopurinmonohydrat - tablett - 50 mg - merkaptopurinmonohydrat 50 mg aktiv substans; laktos (vattenfri) hjälpämne
clarithromycin hec 500 mg depottablett
hec pharm gmbh - klaritromycin - depottablett - 500 mg - klaritromycin 500 mg aktiv substans; laktosmonohydrat hjälpämne - klaritromycin
mykofenolatmofetil actavis 250 mg kapsel, hård
ebb medical ab - mykofenolatmofetil - kapsel, hård - 250 mg - natriumlaurilsulfat hjälpämne; propylenglykol hjälpämne; mykofenolatmofetil 250 mg aktiv substans
mykofenolatmofetil orifarm 250 mg kapsel, hård
orifarm ab - mykofenolatmofetil - kapsel, hård - 250 mg - propylenglykol hjälpämne; mykofenolatmofetil 250 mg aktiv substans; natriumlaurilsulfat hjälpämne
mykofenolatmofetil actavis 250 mg kapsel, hård
2care4 aps - mykofenolatmofetil - kapsel, hård - 250 mg - mykofenolatmofetil 250 mg aktiv substans; propylenglykol hjälpämne; natriumlaurilsulfat hjälpämne
omblastys
y-mabs therapeutics a/s - iodine (131i) omburtamab - neuroblastom - terapeutiska radioaktiva läkemedel - treatment of neuroblastoma.
nucala
glaxosmithkline trading services - mepolizumab - astma - läkemedel mot obstruktiv lungsjukdom, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.
xolair
novartis europharm limited - omalizumab - asthma; urticaria - läkemedel mot obstruktiv lungsjukdom, - allergiska asthmaxolair är indicerat hos vuxna, ungdomar och barn (6 till.
paclitaxel accord 6 mg/ml koncentrat till infusionsvätska, lösning
accord healthcare b.v. - paklitaxel - koncentrat till infusionsvätska, lösning - 6 mg/ml - makrogolglycerolricinoleat hjälpämne; etanol, vattenfri hjälpämne; paklitaxel 6 mg aktiv substans - paklitaxel
adakveo
novartis europharm limited - crizanlizumab - anemi, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.